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Objective: This study aimed to confirm the diagnosis of AML-M3 and the 
frequency of occurrence of the breakpoint cluster region (bcr1) in patients 
provisionaly diagnosed according to FAB classification. Cytologenetic and 
molecular genetics methods were used.
Methods: Bone marrow (BM) or Peripheral Blood (PB) samples collected 
from 27 AML-M3 patients (During the period 2005 through 2007) were 
subjected to conventional karyotyping G-banding, detection of t (15;17) was 
performed by Fluorescence In Situ Hybridization (FISH) and PML-RARA gene 
rearrangements were detected by Quantitative Real-Time Reverse Transcriptase 
Polymerase Chain Reaction (QR-RT-PCR). 
results: Karyotyping was successful in 24 out of 27 samples. Four patients out 
of 24 had a t (15;17), 17 had normal karyotype and 3 had other abnormalities. 
The results obtained by FISH technique corresponded with karyotype results 
and revealed positivity in another 3 samples. QR-RT-PCR demonstrated bcr1 
positivity in the 4 patients diagnosed by Karyotyping with t (15;17) and in the 
8 patients can not diagnosed by Cytogenetic methods.
conclusion: Despite the fact that cytogenetics permit the identification of many 
chromosomal changes within a sample, FISH analysis is more sensitive when 
the karyotype fails to find out the t (15;17). Furthermore, QR-RT-PCR appears 
to be the only suitable approach to detect the molecular events underlying 
hematological malignancies and provides informations on the correlation 
between different levels of disease at early phases of therapy and clinical 
outcome.
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intrODUctiOn                                                                     
Acute promyelocytic leukemia (APL) 
is a distinct subtype of acute nonlym-
phocytic leukemia with unique clinical, 
cytologic, and cytogenetic features.1
Recognition of this subtype of leukemia 
is important because of its potential life-
threatening disseminated intravascular 
coagulation and clinical response to all-
trans retinoic acid (ATRA) treatment.2 
APL accounts for 10-15% of the de 
novo AML in younger adults3 and is 
characterized by a reciprocal transloca-
tion involves chromosomes 15 and 17.4 
The two genes fused in the t (15;17) are 
promyelocytic leukemia (PML) gene, 
located on chromosome 15, and the 
retinoic acid receptor α (RARA) gene 
on chromosome 17. Other genes have 
been shown to be fused to RARA in 
rare instances of morphological APL 
cases negative for the t (15;17), such as 
Promyelocytic Leukemia Zinc Finger 
(PLZF) on chromosome 11q23, nucleo-
phosmin (NPM) on 5q35, nuclear mi-
totic apparatus (NUMA) on 11q13 and 
single transducer and activator of tran-
scription (STAT5b) on 17q21.3
RARA breakpoints always occur in in-
tron 2 which is 17kb in length. On the 
contrary, three regions of the PML lo-
cus are involved in the t (15;17) translo-
cation breakpoints: intron 6 (bcr1;55% 
of cases), exon 6 (bcr2; 5%) and intron 
3 (bcr3;40%). Consequently, there are 
three possible PML-RARA isoforms, 
referred to as long (L, or bcr1), variant 
(V, or bcr2) and short (S, or bcr3). Chi-
meric PML-RARA and RARA-PML 
transcripts are formed as a consequence 
of the reciprocal translocation between 
the PML and RARA loci.3
To our knowledge this study was the 
first in Syria and aimed to confirm the 
diagnosis of AML-M3 and the fre-
quency of occurrence of the breakpoint 
cluster region (bcr1) in patients primi-
tively diagnosed according to French-
American-British (FAB) classification. 
Cytogenetical and molecular methods 
were used.
SUBjectS anD MetHODS                       
Twenty-seven samples were prospec-
tively analyzed, collected from AML-
M3 patients treated in Damascus Uni-
versity Hospitals (Al-Mowasah, Nucle-
ar Medicine Center and Al-Assad Uni-
versity Hospital) during the period 2005 
through 2007, primarily diagnosed after 
retrospective retrieving of their clinical 
manifestations, total blood counts, mor-
phological study (FAB classification) 
and cytochemistry staining. Informed 
consent was obtained from all subjects 
prior to their inclusion in the study.
Bone marrow (BM) or peripheral blood 
(PB) samples were cultured in RPMI 
1640 medium (Chromosome Medium 
A, Biochrom AG, Berlin, Germany) for 
24-48 hours and Karyotypes were de-
termined with the use of Giemsa Band-
ing technique (GTG banding).5 At least 
20 metaphases were analyzed to iden-
tify the genetic abnormalities obtained 
from two different cell cultures.
The FISH technique was applied with 
a PML (15q22)/RARA (17q21) Dual-
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Color, Dual-Fusion DNA probe, (Q-
BIOgene, Heidelberg, Germany), ac-
cording to the manufacturer’s instruc-
tions.
At least 50 isolated cells per slide were 
counted. A red dot (Rhodamine) corre-
sponded to the RARA gene and a green 
dot (Fluorescein) to PML gene. Thus, 
when one cell with two isolated red 
dots and two isolated green  dots were 
observed, it was counted as  normal, 
without rearrangement. When a cell 
with one isolated red dot, one isolated 
green dot and one fused green and red 
signal were seen it was considered to 
represent rearrangement.
RNA was extracted using Invisorb® 
Spin Blood RNA Mini Kit (Roboscreen, 
Leibzig, Germany), Reverse tran-
scription was performed using cDNA 
Synthesis Kit (BioLine GmbH, Luck-
enwalde, Germany) under conditions 
recommended by the manufacturer. 
Quantification of PML-RARA fusion 
transcripts, breakpoint region of PML 
locus: intron 6 (bcr1) were performed 
using LightCycler instrument (Roche, 
Mannheim, Germany) and following 
the procedure recommended by Robo-
Gene® PML-RARA cDNA Quantifi-
cation kit (Roboscreen, Leibzig, Ger-
many).
In order to always confirm the integrity 
of our samples as well as to correct for 
RNA load, cDNA synthesis efficiency, 
PCR inhibitors and possible analyte 
loss during long-time storage, the data 
obtained had to be normalized to the 
number of c-ABL (Abelson) reference 
gene. PML-RARA and c-ABL tran-
script copy numbers were determined at 
the first real-time PCR cycle in which 
the initiation of exponential cDNA tem-
plate amplification exceeds background 
by 10-fold (The threshold cycle [CT]) 
and by reference to plasmid DNA stan-
dard curves.
PML-RARA values were reported as 
the normalized quotient (NQ), derived 
by dividing the PML-RARA copy num-
ber by the c-ABL copy number.
reSUltS                                                        
Twenty seven cases were already   stud-
ied following the provisional diagnosis 
protocol, all had typical clinical aspects 
of AML with suspicion of APL at di-
agnosis. 13 of the 27 patients (48%) 
were males and 14 (52%) were females, 
aged ranged between 14 and 73 years 
(Table1). 
Cytogenetic investigation was success-
ful in 24 out of 27 samples (88.8%): 1 
sample had a t (8;21)(q22;q22) and an-
other sample had a t(9;22) (q34;q11) 
accordingly these two samples were 
excluded from further investigation by 
other techniques since they are cor-
related with other leukemia subtypes. 
4 samples out of the 24 showed a t 
(15;17) (q22;q21) using cytogenetic 
technique which was also confirmed 
by FISH technique. Although 17 sam-
ples showed normal karyotypes, 3 out 
of them proved to have t (15;17) when 
FISH method was used.
The remaining one sample out of the 
24 showed a complex karyotype which 
included terminal deletion in chromo-
some 5, trisomy in chromosome 8 and 
21. Translocation (15;17) was suspected 
in one cell of this sample, hence it was 
subjected to FISH  technique which 
revealed the presence of t (15;17) 
(q22;q21) table (1).
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table 1: Demonstration of bcr1 in primarily diagnosed APL patients visited Al-Mowasah, Nuclear 















































 * M= male; F=female.
†  primary diagnosis by clinical manifestation, morphologic study according to FAB classification, total blood 
count, cytochemistry study…etc., retrospectively.
‡  APL=Acute Promyelocytic Leukemia.
§  AML=Acute Myelocytic Leukemia.
** The complete representation of chromosome aberrations is noted by a combination of symbols that identify: the 
total number of chromosomes, the sex-chromosome complement, any chromosome(s) that are too few or too many, 
and/or any chromosome aberration(s) and their location on the chromosome(s) involved.
††  46, XY, t(15;17)=Male karyotype with 46 chromosomes and a translocation between chromosome 15 and 
chromosome 17.
‡‡  47, XY, del 5q15-q ter,+8=Male karyotype with 47 chromosomes, terminal deletion in q arm of chromosome 5 
with break in band 5q15 and an extra chromosome 8 (trisomy 8) accompanied with poor prognosis.
§§  47,XY,del 5q15-q ter,+21=Male karyotype with 47 chromosomes, terminal deletion in q arm of chromosome 5 
with break in band 5q15 and an extra chromosome 21 (Trisomy 21) accompanied with poor prognosis.
***  W=Without material (Metaphases, cells).
†††  The PML-RARA dual color translocation probe is used to detect t(15;17) which involves the PML region on 
15q22 and RARA on 17q21.
‡‡‡  bcr1 : breakpoint region of PML locus: intron 6.
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QR-RT-PCR technique was carried 
out on 24 samples (2 samples out of 
the original 27 were excluded based 
on irrelevant karyotype abnormalities 
irrelative karyotype profiles and an-
other one for the unavailability of ad-
equate sample) including the 3 samples 
which failed karyotyping (Sccidental 
cell culture failure). Breakage in bcr1 
region was found in 12 samples, 4 of 
which showed t (15;17) by both GTG 
banding technique and FISH technique. 
Another one sample out of the 12 sam-
ples demonstrated also the presence of 
t (15;17) using FISH method. The re-
maining 7 samples which proved the 
presence of the long transcript (bcr1) 
by QR-RT-PCR, showed normal pro-
files in the other two techniques. On the 
other hand, one out of the 12 samples 
expressed the absence of bcr1 gene re-
arrangement, had revealed a t (15;17)
(q22;q21) when carried out using FISH 
technique table(1).
Fig. 1: Patient with a t (8;21) (q22;q22), accompanied with AML-M2.
Fig. 2a: Patient with a t (15;17) (q22;q21), accompanied with AML-M3 (APL).
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Fig. 2b: Patient with a t (15;17) (q22;q21), using FISH technique on Interphase cells.
Fig. 3: Patient with a t (9;22) (q34;q11), Philadelphia chromosome, accompanied with CML.
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Fig. 4: Patient with a terminal deletion 5q-, and a trisomy 8, accompanied with MDS.
DiScUSSiOn                                                 
Acute promyelocytic leukemia (APL) 
with t (15;17) (q22;q21) is an acute 
myeloid leukemia in which abnormal 
promyelocytes predominate. The dis-
ease can occur at any age but patients 
are predominantly adults in mid-life.6 
Our results showed that there is no cor-
relation between age and disease which 
agrees with Schoch et al. findings7, fur-
thermore our results showed no correla-
tion to gender. 
Karyotype is a key indicator of progno-
sis in AML. The presence of t (15;17) 
is thought to be linked closely to M3 
phenotype, consequently karyotyp-
ing succeed to exclude the 2 suspected 
samples thought to be AML-M3 by pri-
mary clinical diagnosis, and proved the 
existence of a t (8;21) (q22;q22) which 
is related with acute  myeloblastic leu-
kemia with maturation (AML-M2), and 
the existence of a t (9;22) (q34;q11) 
which had promyelocytes >30% and 
marrow blasts >10%, so this patient was 
diagnosed as having Chronic Myeloid 
Leukemia (CML) in accelerated phase 
(AP) or blastic phase (BP). These data 
agree with previous reports of Schoch 
et al.8 and Mrózek et al.9 
In our study, the identification of 
t (15;17) (q22;q21) using GTG-band-
ing technique showed that cytogenetic 
investigation alone may not be sensi-
tive enough to detect the malignant cell 
clone, and the presence of a normal 
karyotype is useless in diagnosis and 
classification of AML. These findings 
agree with Chauffaille et al. study re-
sults10, which recommended also to 
keep on using conventional cytogenetic 
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method, since complex translocations 
involving more than two chromosomes, 
or other abnormalities in addition to the 
t (15;17) are detected only by this meth-
od, as demonstrated previously.10
The advantage of FISH over con-
ventional cytogenetic method is that 
known chromosomal aberrations can 
be checked on interphase nuclei. In 
this manner a large number of cells can 
be evaluated, even if the chromosome 
morphology and spreading do not al-
low chromosomal analysis. Also, cells 
which have not entered mitosis and pos-
sibly represent a distinct biological enti-
ty can be included in the examination.11 
In our study FISH analysis confirmed 
the results obtained with conventional 
cytogenetic method and revealed their 
reliability.
Still, FISH analysis is undoubtedly 
more sensitive than conventional cyto-
genetic method and very useful tool in 
detecting PML/RARA in those patients 
where the karyotype failed to find out 
this translocation, as reported by sev-
eral groups Olshanskaya Olshanskaya 
et al.12, and Shivakumar.13
Comparing Karyotyping and FISH 
to QR-RT-PCR technique, there were 
good correlations between the results of 
the three methods, and showed that QR-
RT-PCR is the most sensitive, accurate 
and reproducible method in detecting 
PML-RARA (bcr1) gene rearrangement 
and it might identify low-level thresh-
old of clinical disease when the pres-
ence of any abnormality was difficult to 
be found by using cytogenetic methods. 
These results agree with Lo Coco14, Bi-
ondi15 and San Miguel16 reports.
In addition, peripheral blood samples 
proved to be convenient for this analy-
sis and provide a good resource to avoid 
the problems of bone marrow aspira-
tion.
QR-RT-PCR assay conditions and 
evaluation criteria were verified to 
enable effective measuring of PML-
RARA mRNA expression levels and 
APL monitoring which was superior to 
non quantitative manual RT-PCR (mrt 
PCR). procedures, with greater than 10-
fold higher sensitivity (The sensitivity 
of QR-RT-PCR was between 10-5 and 
10-6).17
Normalization of the data obtained to 
the number of a reference gene (c-ABL 
gene) was done to confirm the integrity 
of the samples, as well as to correct for 
RNA load and cDNA synthesis efficien-
cy and which was justified by Beillard 
et al. who evaluated many reference 
gene for data normalization when QR-
RT-PCR is used.18
Principally, the detection of t (15;17) 
and/or PML/RARA fusion transcript 
is essential for all clinically suspected 
APL cases. In our study, bcr1 transcript 
was positive in 50% of patients using 
QR-RT-PCR. Hence, these results sup-
port the role of molecular techniques to 
confirm the diagnosis, furthermore, pa-
tients would benefit consequently ATRA 
induction therapy. Exact quantification 
of PML-RARA fusion transcripts by 
real-time pcr is the promising technique 
of choice to follow up patients and study 
the kinetics of transcript disappearance 
in remission cases. Thus, patients who 
are in pending relapse and who require 
further therapeutic intervention can be 
distinguished as Schnittger et al.19 also 
mentioned. 
Therefore, we recommend to use QR-
RT-PCR as an essential tool for detect-
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ing the molecular events underlying he-
matological malignancies and to define 
correlations between the amount of fu-
sion products and clinical outcome es-
pecially after treatment. 
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